Global Journal of Engineering and Technology [GJET].
ISSN: **2583-3359** (Online)
Frequency: Monthly
Published By GSAR Publishers
Journal Homepage Link- https://gsarpublishers.com/journal-gjet-home/

Cyclosporine A Mycosynthesis and Its Clinical Significance

BY

Nida tabassum khan

Department of Biotechnology, Faculty of Life Sciences & Informatics, Balochistan University of Information Technology, Engineering and Management Sciences, Takatu Campus, Airport Road, Quetta, Balochistan

Article History
Received: 02/08/2022
Accepted: 26/08/2022
Published: 28/08/2022
Vol – 1 Issue – 3
PP: - 25-27

Abstract:
Tolypocladium inflatum is a fungus at first isolated from Norwegian soil and has for quite some time been of interest in biotechnology because of its capability toproduce non-cytotoxic, normal 11 amino acids and the cyclic peptide cyclosporine A. cyclosporine A is an immunosuppressant narrow spectrum antifungal peptide and is utilized in heart, liver, and kidney transplantations.

KEYWORDS:*Immunosuppressant;Thioesters; Autoimmune;Transplantation;Interleukin*

Introduction

Cyclosporine A (CsA) is generally produced by the aerobic fungi*Tolypocladium inflate* through submerged fermentation [1]. Cyclosporine A from the pathogenic fungus *Tolypocladium inflatum*exhibited antifungal properties and later developed as an immunosuppressant medicine[2,3]. Absence of CsA gene in the fungi showed hindered parasitic virulence against insect host [4]. In addition,CsA gene and transporter genes together provide tolerance in fungi against cyclosporine [5].Cyclosporine produced by *Tolypocladium inflatum*also increase fungal abilities to compete with other parasitic fungi and infect insect hosts for survival and reproduction [6,7].

Production of cyclosporine from *Tolypocladium inflatum*

Different strains of*Tolypocladium inflatum* produces cyclosporine A, B , and C [8]. Cyclosporine A (CsA) is a cyclic undecapeptide, perhaps the most routinely given immunosuppressive medicine [9]. The filamentous growth of *Tolypocladium inflatum* produces it non-ribosomally from a multifunctional cyclosporin synthetase protein complex [10]. Every one of the three culture stages (sporulation culture, development culture, and production culture) was enhanced consecutively to augment the synthesis of CsA by wild-type *Tolypocladium inflatum* [11,12]. The SSMA medium along with valine and fructose is fundamental for CsA biosynthesis [13]. Phylogenomic examination distinguishes exceptional and complex homology relationship between non-ribosomal peptide synthetase (NRPS) encoding cyclosporin synthetase and other optional metabolites with antimicrobial action, replication mechanism, and hereditary combination in NRPS arrangement [14,15]. Another metabolite-associated gene named cyclophilin for cyclosporine biosynthesis was discovered in *Tolypocladium inflatum* [16]. It belongs to the immunophilins family known for binding cyclosporine [17]. Similar investigation upholds the particular beginning of cyclosporinegene succession as opposed to gene exchange from microbes or different growths [18]. The *inflatum* genome gives further comprehension of the advancement and biosynthesis of cyclosporine and establishes the groundwork for an additional examination of the role of hereditary changes of the subsequent metabolite and its metabolites in mycology [19,20]. Cyclosporine A is produced by cyclosporine synthetase, a multienzyme polypeptide that catalyzes no less than 40 steps to enacts all constituent amino acids of cyclosporine A to thioesters through amino acyladenylates and does explicit N-methylation [21,22]. During extension, the set-off amino acids are connected by peptide bonds prompting the chemical-bound beginning of peptide chains [23]. A portion of the immediate peptides of the developing cyclosporine A chain were isolated and their N-terminal amino acid was identified [24].

Medical use of Cyclosporine A

Some uses are as follows:

- Cyclosporine A is utilized as medicine to treat immune system conditions available in various forms including oral solutions/capsules, and eye drops [25].
- Cyclosporine A helps to prevent organ/tissue rejection during transplantation [26,27]

- It is used to treat rheumatoid arthritis, psoriasis, keratoconjunctivitis sicca, meibomian gland dysfunction, nephrotic syndrome, severe ulcerative colitis etc [28,29]
- Cyclosporine Ahas been explored as a potential neuroprotective agent in brain traumas/injury to reduce brain damage [30]. It blocks the formation of mitochondrial permeability pore, which has been acquainted with conjure a large part of the harm related with head injury and neurodegenerative sicknesses [31]. In addition, Cyclosporine A, ability to fix/recuperate neuronal cell harm and reperfusion injury in cerebrum injury is under study [32].
- Cyclosporine A has been utilized tentatively to treat cardiovascular hypertrophy (an expansion in cell volume) [33]. An impaired opening of the mitochondrial porousness progress pore (MPTP) appears in ischemia(bloodstream limitation to tissue) and reperfusion injury (harm occurring after ischemia when bloodstream gets back to tissue), after myocardial localized necrosis [34]. The heart endeavors to make up for the impairment by adding the intracellular Ca2 resulting in unseemly MPTP opening prompting a drop in the cardiovascular capacity [35,36].
- In addition, Cyclosporine Ais endorsed in the United States for the treatment of atopic dermatitis in canines [37]. It's likewise used to treat sebaceous adenitis (invulnerable reaction against the sebaceous organs), pemphigus, myasthenia gravis, etc [38]
- Cyclosporine A primary impact is to bring down the activity of T-cells by binding to the cytosolic protein cyclophilin (immunophilin) of lymphocytes, particularly of T cells [39]. This cyclosporine-cyclophilin complex hinders calcineurin, which is initiates interleukin 2 transcription which is a signaling molecule in the immune system. [40]. It controls the activities of white platelets (leukocytes, much of the time lymphocytes) that are liable for insusceptibility [41].

In spite of the fact that cyclosporine A is a FDA approved medication, at times, it can conceive extreme secondary effects including hypertension, malignant growth, particularly lymphoma and skin disease, gum enlargement, pancreatitis, diarrhea etc [42,43].

CONCLUSION

Thus**,** *Tolypocladium inflatum* is an abundant source of cyclosporine A which is utilized in numerous medical applications.

REFERENCES

1. Tedesco, D., & Haragsim, L. (2012). Cyclosporine: a review. Journal of transplantation, 2012.
2. Cohen, D. J., Loertscher, R., Rubin, M. F., Tilney, N. L., Carpenter, C. B., & Strom, T. B. (1984). Cyclosporine: a new immunosuppressive agent for organ transplantation. Annals of internal medicine, 101(5), 667-682.\
3. Canafax, D. M., & Ascher, N. L. (1983). Cyclosporine immunosuppression. Clinical pharmacy, 2(6), 515-524.
4. Zhang, L., Fasoyin, O. E., Molnár, I., & Xu, Y. (2020). Secondary metabolites from hypocrealean entomopathogenic fungi: Novel bioactive compounds. Natural product reports, 37(9), 1181-1206.
5. Shekhar-Guturja, T. (2016). Utilizing a Microbial Natural Product to Investigate Cellular Circuitry Governing Fungal Drug Resistance and Morphogenesis (Doctoral dissertation, University of Toronto (Canada)).
6. Sharma, M., & Sharma, R. (2016). Drugs and drug intermediates from fungi: Striving for greener processes. Critical Reviews in Microbiology, 42(2), 322-338.
7. Butt, T. M., Coates, C. J., Dubovskiy, I. M., & Ratcliffe, N. A. (2016). Entomopathogenic fungi: new insights into host-pathogen interactions. Advances in genetics, 94, 307-364.
8. Isaac, C. E., Jones, A., & Pickard, M. A. (1990). Production of cyclosporins by Tolypocladium niveum strains. Antimicrobial agents and chemotherapy, 34(1), 121-127.
9. Lazarova, T., & Weng, Z. (2003). Cyclosporin A analogues: recent advances. Expert Opinion on Therapeutic Patents, 13(9), 1327-1332.
10. Velkov, T., & Lawen, A. (2003). Non-ribosomal peptide synthetases as technological platforms for the synthesis of highly modified peptide bioeffectors—cyclosporin synthetase as a complex example. Biotechnol Annu Rev, 9, 151-197.
11. Yang, X., Feng, P., Yin, Y., Bushley, K., Spatafora, J. W., & Wang, C. (2018). Cyclosporine biosynthesis in Tolypocladium inflatum benefits fungal adaptation to the environment. MBio, 9(5), e01211-18.
12. Yang, X., Feng, P., Yin, Y., Bushley, K., Spatafora, J. W., & Wang, C. (2018). Cyclosporine biosynthesis in Tolypocladium inflatum benefits fungal adaptation to the environment. mBio 9: e01211-18.
13. Gupta, V. G., & Pandey, A. (Eds.). (2019). New and Future Developments in Microbial Biotechnology and Bioengineering: Microbial Secondary Metabolites Biochemistry and Applications. Elsevier.
14. Diettrich, M. S. J. Genomics-assisted chemical exploration of the secondary metabolomes of Massilia and Acidovorax species.
15. Kemp, G. C. (2011). Total solid-phase synthesis of the mixirins; antitumour cyclic lipopeptides. University of London, University College London (United Kingdom).
16. Bushley, K. E., Raja, R., Jaiswal, P., Cumbie, J. S., Nonogaki, M., Boyd, A. E., ... & Spatafora, J. W. (2013). The genome of Tolypocladium inflatum: evolution, organization, and expression of the cyclosporin biosynthetic gene cluster. PLoS genetics, 9(6), e1003496.
17. Survase, S. A., Kagliwal, L. D., Annapure, U. S., & Singhal, R. S. (2011). Cyclosporin A—a review on

fermentative production, downstream processing, and pharmacological applications. Biotechnology advances, 29(4), 418-435.
18. Spatafora, J. W., & Bushley, K. E. (2015). Phylogenomics and evolution of secondary metabolism in plant-associated fungi. Current opinion in plant biology, 26, 37-44.
19. Řeháček, Z., & De-xiu, Z. (1991). The biochemistry of cyclosporin formation: a review. Process biochemistry, 26(3), 157-166.
20. Galat, A. (2003). Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Current topics in medicinal chemistry, 3(12), 1315-1347.
21. Lawen, A., & Zocher, R. (1990). Cyclosporin synthetase. The most complex peptide synthesizing multienzyme polypeptide so far described. Journal of Biological Chemistry, 265(19), 11355-11360.
22. Stein, T., & Vater, J. (1996). Amino acid activation and polymerization at modular multienzymes in nonribosomal peptide biosynthesis. Amino acids, 10(3), 201-227.
23. Hoppert, M., Gentzsch, C., & Schörgendorfer, K. (2001). Structure and localization of cyclosporin synthetase, the key enzyme of cyclosporin biosynthesis in Tolypocladium inflatum. Archives of microbiology, 176(4), 285-293.
24. Sieber, S. A., & Marahiel, M. A. (2005). Molecular mechanisms underlying nonribosomal peptide synthesis: approaches to new antibiotics. Chemical reviews, 105(2), 715-738.
25. Nussenblatt, R. B., & Palestine, A. G. (1986). Cyclosporine: immunology, pharmacology, and therapeutic uses. Survey of ophthalmology, 31(3), 159-169.
26. Gorantla, V. S., Barker, J. H., Jones Jr, J. W., Prabhune, K., Maldonado, C., & Granger, D. K. (2000). Immunosuppressive agents in transplantation: Mechanisms of action and current anti-rejection strategies. Microsurgery: Official Journal of the International Microsurgical Society and the European Federation of Societies for Microsurgery, 20(8), 420-429.
27. Baskette, K. G. (2010). Organ Harvesting and Transplants. Technology and Engineering Teacher, 69(7), 5.
28. Creuzot-Garcher, C. (2001). Systemic Diseases and Conjunctivitis. Inflammatory Diseases of the Conjunctiva, 143.
29. Fong, D. S., Law, S. K., & Schmidt-Erfurth, U. (Eds.). (2006). Drugs in ophthalmology. Berlin, Heidelberg: Springer Berlin Heidelberg.
30. Osman, M. M., Lulic, D., Glover, L., Stahl, C. E., Lau, T., van Loveren, H., & Borlongan, C. V. (2011). Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application. Neuropeptides, 45(6), 359-368.
31. Hagl, C., Tatton, N. A., Weisz, D. J., Zhang, N., Spielvogel, D., Shiang, H. H., ... & Griepp, R. B. (2001). Cyclosporine A as a potential neuroprotective agent: a study of prolonged hypothermic circulatory arrest in a chronic porcine model. European journal of cardio-thoracic surgery, 19(6), 756-764.
32. Kilbaugh, T. J., Bhandare, S., Lorom, D. H., Saraswati, M., Robertson, C. L., & Margulies, S. S. (2011). Cyclosporin A preserves mitochondrial function after traumatic brain injury in the immature rat and piglet. Journal of neurotrauma, 28(5), 763-774.
33. CreSpo-Leiro, M. G. (2003, August). Tacrolimus in heart transplantation. In Transplantation proceedings (Vol. 35, No. 5, pp. 1981-1983). Elsevier.
34. Meguro, T., Hong, C., Asai, K., Takagi, G., McKinsey, T. A., Olson, E. N., & Vatner, S. F. (1999). Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circulation Research, 84(6), 735-740.
35. Molkentin, J. D. (2000). Calcineurin and beyond: cardiac hypertrophic signaling. Circulation Research, 87(9), 731-738.
36. Ding, B., Price, R. L., Borg, T. K., Weinberg, E. O., Halloran, P. F., & Lorell, B. H. (1999). Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circulation Research, 84(6), 729-734.
37. Olivry, T., DeBoer, D. J., Favrot, C., Jackson, H. A., Mueller, R. S., Nuttall, T., & Prélaud, P. (2015). Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Veterinary Research, 11(1), 1-15.
38. Morris, D. O., & Kennis, R. A. (2012). Clinical dermatology, an issue of veterinary clinics: small animal practice (Vol. 43, No. 1). Elsevier Health Sciences.
39. McCaffrey, P. G., Perrino, B. A., Soderling, T. R., & Rao, A. (1993). NF-ATP, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. Journal of Biological Chemistry, 268(5), 3747-3752.
40. Baumann, G., Zenke, G., Wenger, R., Hiestand, P., Quesniaux, V., Andersen, E., & Schreier, M. H. (1992). Molecular mechanisms of immunosuppression. Journal of autoimmunity, 5, 67-72.
41. Rovira, P., Mascarell, L., & Bachi, P. T. (2000). The impact of immunosuppressive drugs on the analysis of T-cell activation. Current medicinal chemistry, 7(7), 673-692.
42. Graham, R. M. (1994). Cyclosporine: mechanisms of action and toxicity. Cleveland Clinic journal of medicine, 61(4), 308-313.
43. Ryffel, B., Foxwell, B. M., Gee, A., Greiner, B., Woerly, G., & Mihatsch, M. J. (1988). Cyclosporine--relationship of side effects to mode of action. Transplantation, 46(2 Suppl), 90S-96S.